CD38 and amyloidosis: However, a non‐negligible proportion of patients received a melphalan‐based chemotherapeutic approach as the first line of therapy, whereas the current standard of care for patients with amyloidosis is based on the combination of the monoclonal antibody against CD38 daratumumab in addition to bortezomib and cyclophosphamide in many countries [21, 38, 39].